Novel therapeutic approaches in chronic myeloid leukemia

ÖZGÜR YURTTAŞ N., EŞKAZAN A. E.

LEUKEMIA RESEARCH, vol.91, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 91
  • Publication Date: 2020
  • Doi Number: 10.1016/j.leukres.2020.106337
  • Journal Name: LEUKEMIA RESEARCH
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Istanbul University Affiliated: No

Abstract

The tyrosine kinase inhibitors (TKIs) have revolutionized the management of chronic myeloid leukemia (CML) and BCR-ABL1 inhibitors form the mainstay of CML treatment. Although patients with CML generally do well under TKI therapy, there is a subgroup of patients who are resistant and/or intolerant to TKIs. In these group of patients, there is the need of additional treatment strategies. In this review, we provide an update on the current knowledge of these novel treatment approaches that can be used alone and/or in combination with TKIs.